Clinical Trial Update: Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update on the ALVAC-HIV vCP1452 vaccine evaluating its use with intermittent anti-HIV drug withdrawal in HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• ALVAC-HIV vCP1452

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED